What is NuSirt Sciences?
NuSirt Sciences operates at the intersection of pharmaceutical innovation and metabolic health, focusing on the development of therapies that mitigate the effects of chronic conditions such as obesity, type 2 diabetes, and hypertension. The company's research methodology centers on the assessment of natural compounds and pharmaceutical agents, validated through rigorous clinical trials. Their product pipeline includes the combination therapy TRIPLN and the dietary supplement LEUSIX, both designed to support cardiometabolic health. By targeting the underlying mechanisms of metabolic dysfunction, NuSirt Sciences provides healthcare professionals and patients with evidence-based options for long-term disease management.
How much funding has NuSirt Sciences raised?
NuSirt Sciences has raised a total of $20.6M across 4 funding rounds:
Series B
$9.1M
Series A
$3.5M
Series C
$6M
Private Equity
$2M
Series B (2014): $9.1M, investors not publicly disclosed
Series A (2014): $3.5M led by William Guttman, Mountain Group Capital, and Tennessee Community Ventures Fund
Series C (2015): $6M supported by TriStar Technology Ventures, Mountain Group Partners, and Hatteras Venture Partners
Private Equity (2016): $2M, investors not publicly disclosed
Key Investors in NuSirt Sciences
TriStar Technology Ventures
TriStar Technology Ventures is a Louisville-based firm providing specialized IT and software services, often supporting the infrastructure needs of growing technology-driven enterprises.
Mountain Group Partners
Mountain Group Partners is a Nashville-based venture capital firm focused on early-stage investments in Life Sciences and AgTech, providing active, long-term partnership to foster innovation.
Hatteras Venture Partners
Hatteras Venture Partners is a seasoned venture capital firm dedicated to building transformative biotech and MedTech companies through strategic support and deep industry expertise.
What's next for NuSirt Sciences?
With the recent capital injection, NuSirt Sciences is well-positioned to accelerate its clinical development programs and expand its market reach. The strategic focus will likely shift toward scaling the commercialization of its existing health solutions while advancing the TRIPLN combination therapy through critical regulatory milestones. As the company transitions into its next phase of growth, the emphasis remains on demonstrating therapeutic efficacy and securing broader adoption among clinical practitioners. This strategic roadmap is designed to enhance the company's valuation and solidify its role as a leader in the specialized field of cardiometabolic therapeutics.
See full NuSirt Sciences company page
